International Edition
Latest News
Technology

Spectris Misses Primary Endpoint in SPINOZA Trial of Obicetrapib for Preclinical Alzheimer’s Disease

The phase 2b SPINOZA trial of obicetrapib failed to meet its primary endpoint of change from baseline to week 52 in plasma p-tau217, Spectris announced Monday. The study enrolled participants with preclinical Alzheimer's disease stratified by APOE genotype.…

Spectris Misses Primary Endpoint in SPINOZA Trial of Obicetrapib for Preclinical Alzheimer's Disease

The phase 2b SPINOZA trial of obicetrapib failed to meet its primary endpoint of change from baseline to week 52 in plasma p-tau217, Spectris announced Monday.

The study enrolled participants with preclinical Alzheimer’s disease stratified by APOE genotype. The primary endpoint measured the percentage change in plasma p-tau217, a blood-based biomarker that rises exponentially in cognitively unimpaired APOE4 carriers after age 65.

Obicetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor developed by NewAmsterdam Pharma, entered the Alzheimer’s pipeline after a prespecified biomarker substudy of the BROADWAY cardiovascular outcomes trial showed the drug blunted the 12-month rise in plasma p-tau217 relative to placebo.

The effect followed an APOE genotype gradient in BROADWAY. The difference widened to 5.74 percentage points in APOE4 carriers (P = .022) and reached 20.48 percentage points in the 29 APOE4 homozygotes, whose p-tau217 levels fell 7.81% on obicetrapib while rising 12.67% on placebo (P = .010).

SPINOZA’s design paired plasma p-tau217 as a primary endpoint with a broader biomarker panel and cognitive and functional assessments. Secondary endpoints included changes in amyloid-beta 42/40 and p-tau217 ratios, brain-derived tau, and the Preclinical Alzheimer’s Cognitive Composite 5 (PACC5).

The trial rationale and design were presented at the 2026 Clinical Trials on Alzheimer’s Disease Conference in Boston on November 16–19, 2026, by M.H. Davidson, M. Ditmarsch, A. Hsieh, A. Walker, A. Johnson, and J.J.P. Kastelein.

Up to 66% of people with Alzheimer’s disease carry at least one APOE4 allele, the strongest known genetic risk factor for the common, late-onset form of the disease.

Plasma p-tau217 has emerged as a reliable biomarker of that pathology. The BROADWAY substudy results, published in the Journal of Prevention of Alzheimer’s Disease (2026;13(1):100394), suggested CETP inhibition could modify this trajectory in a cardiovascular population.

Spectris, founded in 1915 as the Fairey Aviation Company, evolved from manufacturing seaplanes to becoming a global supplier of precision instrumentation and controls. The company was first listed on the London Stock Exchange in 1988 and underwent significant transformations, including acquisitions and divestments, before being acquired by KKR in December 2025.

Known for its strategic focus on high-precision technologies, Spectris built a reputation through notable deals, such as the $475 million acquisition of Omega Engineering in 2011 and the $525 million divestment of Omega Engineering to the Dwyer Group in 2022.

Spectris did not disclose numerical results from the SPINOZA primary endpoint or specify whether secondary or exploratory endpoints showed treatment effects. The company said results are expected to inform the broader clinical development of CETP inhibition as an Alzheimer’s prevention strategy.

About the author: Technology Desk

Technology Desk at Archynewsy.